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Statement of Translational Relevance 
 
Src kinase inhibitors are currently entering phase 3 clinical trials for treatment of 
prostate cancer, the current study demonstrates that only a subset of patients have 
increased Src activity and that these patients have a poor prognosis, relapsing quicker 
and have reduced shorter overall survival.  These results suggest that potentially only 
this subset of patients would respond to this therapy and therefore  it might be 
necessary to select patients prior to receiving Src inhibitors in a similar manner used 
with Herceptin and Tamoxifen in breast cancer.   
 
Abstract 
 
Purpose 
Although SFK inhibitors are now in clinical trials for the treatment of androgen 
independent prostate cancer (AIPC), there are no studies relating SFK activation to 
patient survival.  This study was designed to determine if SFK activation was up-
regulated with the development AIPC and if patients could be selected who were 
more likely to respond to therapy.  
Experimental Design 
A unique cohort of matched prostate tumour samples, taken prior to hormone 
deprivation therapy and following hormone relapse, was used to determine by 
immunohistochemistry on an individual patient basis if SFK activity changed with 
progression to AIPC and whether this related to patient outcome measures.  Using 
matched, hormone sensitive and hormone refractory cell lines, we determined if 
hormone status affected the way prostate cancer cells respond to suppression of SFK 
activity by the small molecule inhibitor dasatinib.  
Results 
In the current study, 28% of patients with AIPC exhibited an increase in SFK activity, 
these patients had significantly shorter time to relapse (P=0.005) and overall survival 
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(P<0.0001) and activated SRK expression correlated with presence of distant 
metastases. Dasatinib inhibited phosphorylation of Src and Lyn and the downstream 
substrate FAK in hormone sensitive and hormone refractory cell lines. Although 
migration was reduced by dasatinib in both cell lines, proliferation of hormone 
refractory cells only was inhibited.  
Conclusion 
Appropriate patient selection may allow better targeting of prostate cancer patients 
who are likely to respond to the treatment with SFK inhibitors at the same time 
improving the outcome of clinical trials.
 4 
Introduction 
Prostate cancer is the most common cancer in men and is the second leading 
cause of cancer related deaths in men in the US and UK (1). Treatment options for 
locally advanced and metastatic prostate cancer are limited to androgen deprivation 
using anti-androgen drugs or surgical castration. Unfortunately, nearly all of these 
patients eventually develop androgen independent prostate cancer (AIPC) for which 
currently there are no established effective therapies. 
Our understanding of the mechanisms involved in the development of AIPC has 
considerably improved over the last decade. When deprived of androgen stimulation, 
androgen sensitive prostate cancer (ASPC) cells develop the ability to survive and 
thrive by up-regulating oncogenic pathways where tyrosine kinases often play a 
crucial role (2). The non-receptor tyrosine kinase Src is thought to facilitate the 
interaction between intracellular molecular cascades as well as form complexes with 
the androgen receptor (AR) which is expressed by the majority of AIPC cells. 
Tyrosine phosphorylation is an important factor in the regulation of AR activity 
resulting in translocation of the receptor into the nucleus and increase in DNA 
synthesis.   Src activation by growth factors in prostate cancer cells has been shown to 
correlate with AR tyrosine phosphorylation, especially under androgen depleted 
conditions. Thus, evidence exists of an important functional relationship between Src 
and AR in prostate cancer which makes it an attractive target in the search of new 
treatment modalities for AIPC (3).  
Deregulation of Src activity rather than its expression is thought to be an 
important factor in oncogenesis. When Src is phosphorylated on tyrosine Y527, the 
molecule is locked in an inactive state, whereas autophosphorylation of tyrosine Y419 
allows the protein to unfold and assume a catalytically active conformation. Inactive 
Src is mostly located in the perinuclear region of the cell while the activated protein 
translocates to the cell periphery towards the inner surface of the cell membrane (4). 
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Apart from Src, other Src-family kinases (SFKs) have also been implicated in 
prostate cancer. CGH analysis of paired prostate cancer samples, taken from patients 
prior to hormone deprivation therapy and following hormone relapse, revealed Fgr 
was significantly amplified in samples from patients with AIPC (5). Another study 
showed that SFK member Lyn could play a role in the development of hormone 
resistance in prostate cancer. Inhibiting the interaction of Lyn with its substrates by 
sequence based peptides induced extensive apoptosis of hormone refractory DU-145 
explants in nude mice (6).  
The dual Src/Abl kinase inhibitor dasatinib has demonstrated effectiveness in 
prostate cancer cell line studies and animal models and a Phase II clinical trial is 
underway to assess its effectiveness in androgen-deprived prostate cancer (7). 
However, several important issues have not yet been resolved. The role of Src in 
tumour cell proliferation remains controversial and, therefore, the conventional 
estimation of treatment outcome by measurement of tumour size may not be 
appropriate. Although evidence supporting the role of Src in cell motility and the 
development of metastatic disease exists, currently, there are no established methods 
to test this in the clinical setting.  Furthermore, due to significant heterogeneity of 
prostate cancer, not every patient with the disease might be suitable for therapy with 
Src inhibitors. The challenge, therefore, is to identify a subset of patients who are 
likely to respond to the treatment using individual tumour profiling, for example, and 
develop a more targeted approach on the basis of this. Estimation of phospho SrcY419 
(activated form of SFKs) as a biomarker has previously been suggested for this 
purpose (8,9). 
The major drawback of existing cell line studies, investigating the role of Src 
inhibitors in prostate cancer (10-12), is the use of DU-145 and PC-3 cell lines that 
unless specifically introduced, conventionally do not express AR and as the majority 
of tumours in our study do express the AR it would be useful to also study AR 
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positive hormone refractory cell line. However Chang et al recently investigated a 
series of prostate cancer cell lines and reported that the cells that expressed the highest 
levels of Src, were those with the lowest activated/total Src ratios (13).  In addition 
they reported that Src mediates cell proliferation in DU15 and PC3 cells, but 
demonstrate that the mechanism between both cell lines was different (13).  It is 
therefore possible that hormone refractory AR positive cells would also employ a 
different mechanism. Park et al. used PC-3AR-A1, a AR expressing variant of PC-3 
cells  and the highly tumorigenic PC-3MM2GL cell line in an animal model to 
compare the response of primary tumours and the incidence of lymph node metastases 
after treatment with dasatinib (14).  There was no difference between the two cell 
lines, both types of primary tumours were reduced in size compared to controls as was 
the incidence of lymph node metastases, although AR expressing implants tended to 
grow slower. In our in vitro experiments, we used LNCaP cells which depend on 
androgens for their growth and, therefore, respond to androgen stimulation and 
LNCaP-SDM cells which were derived from LNCaP cells by gradual withdrawal of 
androgens from the culture medium (15). Although they retain the ability to respond 
to androgen stimulation, LNCaP-SDM cells are routinely cultured in dextran 
charcoal-stripped foetal calf serum, containing similarly low concentration of 
androgens as in the serum of patients undergoing hormone deprivation therapy. More 
importantly, LNCaP-SDM cells express AR as in the significant majority of prostate 
tissue specimens taken from patients with hormone refractory prostate cancer, and 
therefore represent a possible model of AIPC (16-17).  
To our knowledge, up until now there have been no publications demonstrating 
correlation of SFK expression and activation with clinical parameters including 
survival in prostate cancer.  To address this issue, we investigated SFK expression 
and activation by immunohistochemistry (IHC) in paired prostate tissue samples taken 
from patients prior to androgen deprivation therapy and following hormone relapse. 
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Here, for the first time we show that in a subset of prostate cancer patients an increase 
in SFK activity in AIPC samples compared to ASPC, as indicated by pSrcY419 
immunostaining, is associated with a significant decrease in survival.  Our tissue 
culture experiments have shown that treatment with dasatinib resulted in inhibition of 
proliferation and migration of LNCaP-SDM cells while only migration was 
suppressed in the parental LNCaP cell line, suggesting that inhibition of SFKs may 
provide therapeutic benefit in AIPC. 
 
Materials and Methods 
Patient cohort characteristics.  Ethical approval was obtained for the patients’ 
recruitment from Multiple Research Ethics Committee (MREC) for Scotland. 
Application was subsequently submitted for the site-specific assessment and 
permission to recruit was granted by the Local Research Ethics Committees (LREC). 
No patients in this study had neoadjuvant radiotherapy or androgen deprivation 
therapy.  Each patient in our cohort was required to have tissue sample taken prior to 
hormone deprivation therapy by means of trans-urethral resection of the prostate 
(TURP) or trans-urethral ultrasound (TRUS) biopsy of prostate, more than 50% fall in 
PSA as an indicator of response to androgen deprivation therapy, subsequent 
hormonal therapy was then administered to which the patient did not respond and 
PSA concentrations continued to rise above the PSA nadir to concentrations greater 
than 0.2ng/ml. The second tissue sample was taken after failure to respond to the 
second hormonal therapy and following at least 2 sequential rises in PSA level above 
0.2ng/ml, indicating biochemical relapse. Clinical data, recorded for each patient 
included age (median 70, inter quartile range 66-73), PSA at diagnosis (median 110 
ng/ml, inter quartile range 20-780), PSA at relapse (median 10 ng/ml, inter quartile 
range 4-11), Gleason grade at diagnosis (median 7, range  4-9) and Gleason grade at 
 8 
relapse (median 8, range 6-10).  All patients under went biochemical relapse (median 
time to relapse 2.53 years, inter quartile range 1.57-4.43 years).  At last follow-up, 34 
patients had died of their disease and 12 patients had died of other causes, median 
follow up was 8.3 years and inter quartile range was 5.2-9.1 years.  Following 
diagnosis 10 % (5/50) patients received surgical orchidectomy and 90% (45/50) 
patients received LHRH analogue in combination with anti androgen therapy.  
Following biochemical relapse 64% (32/50) patients received radiotherapy, no 
patients in the current cohort received taxane therapy. Formalin fixed paraffin 
embedded tissue blocks were retrieved for each patient and 5 µm sections were cut 
using Leica RM 1235 microtome and applied onto silane-coated glass slides.  
Immunohistochemistry.  Tissue sections were dewaxed in xylene and rehydrated 
in graded alcohol. Antigen retrieval was performed under pressure for 5 min in citrate 
buffer (pH adjusted to 6.0). Endogenous peroxidase was blocked in 0.3% hydrogen 
peroxide for 10 min and blocked using 1.5% horse serum. Incubation with primary 
antibody was performed in humidified chamber overnight at 40C (anti-phospho 
SrcY419 1:250 and anti-phospho SrcY530 1:100, Cell Signalling Technologies, FGR 
1:100, Abgent and Lyn 1:10, BD Biosciences) or for 1 hour at room temperature for 
total Src (1:1000, Cell Signalling Technologies). Tissue was then incubated in 
Envision solution (DAKO, UK) for 30 min and developed by application of  3,3’-
diaminobenzidine (DAB) as a chromogen (DAKO, UK). Sections were 
counterstained with haematoxylin, dehydrated through graded alcohol and xylene and 
mounted in DPX.  In each immunohistochemistry run LNCaP cell pellets and colon 
tissue is included as positive controls and an isotype matched antibody is used on 
colon samples to provide a negative control. 
Scoring method. Protein expression levels were assessed blindly by 2 independent 
observers, using a weighted histoscore method also known as the H-Score at 
magnification x 400 (18,-19).  Each cellular location (membranes, cytoplasm and 
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nuclei) were scored separately. The weighted histoscore method assesses the staining 
intensity and the percentage of cells stained with that intensity for the full slide.  It is 
calculated by: (1 x % cells staining weakly positive) + (2 x % cells staining 
moderately positive) + (3 x % cells staining strongly positive). This provides a semi-
quantitative classification of staining intensity, with the maximum score being 300 (if 
100% of cells stain strongly positive) and minimum score being 0 (if 100% or cells 
are negative).  The weighted histoscore method is a well established method for 
scoring tissue that has heterogeneous staining (18-19). 
 
Cell culture.  Prostate cancer cell lines LNCaP and LNCaP-SDM were a kind gift 
from Professor C Robson (Northern Institute for Cancer Research, Newcastle). 
LNCaP cells were routinely maintained in RPMI 1640 (Invitrogen, UK) containing 
phenol red and supplemented with 10% foetal calf serum (Invitrogen, UK), and 1% 
glutamine. LNCaP-SDM cells have been developed using parental LNCaP cells as a 
model of hormone resistant prostate cancer by gradual withdrawal of androgens from 
the medium. These cells were routinely cultured in RPMI 1640 supplemented with 
1% glutamine and 10% charcoal-stripped foetal calf serum (Cambrex, UK) known to 
contain negligible amount of androgens.   
Western blot analysis. Cells were lysed in RIPA buffer (50 mM Tris pH7.6, 150 
mM sodium chloride, 1% Triton X-100, 0.5% deoxycholate, 0.1% SDS, 10 mM 
sodium fluoride, 1 mM sodium ortho-vanadate and 1:100 Calbiochem protease 
inhibitor cocktail set 1) and centrifuged at 12 000 rpm for 10 min, the supernatant 
removed and protein concentration determined using BCA/CuSO4 assay. 40 µg of 
protein per well was resolved by 4-12% gradient Bis-Tris gel electrophoresis 
(Invitrogen, UK); proteins were transferred to nitrocellulose membranes (Millipore, 
UK), which were blocked for 1 hour in 5% BSA and probed with primary antibodies: 
anti-phospho SrcY419 (1:10000), anti-total Src (1:10000 Cell Signaling Technologies, 
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UK), anti-phospho FAKY397 (1:10000), anti-phospho FAK861 (1:10000 Biosourse, 
Belgium), anti-total FAK (1:10000 BD Biosciences, UK) at 40C overnight. 
Membranes were then incubated with secondary antibodies (anti-rabbit 1:5000 or 
anti-mouse 1:5000, Cell Signalling Technologies) and visualized with ECL kit 
(Amersham, UK). Where necessary, the membranes were stripped by incubating with 
Re-Blot Plus stripping buffer (Chemicon, UK) before re-probing with other antibodies 
including anti-αTubulin (1:8000 Santa Cruz, USA) to confirm equal protein loading. 
Steroid exposure and withdrawal experiment.  LNCaP and LNCaP-SDM cells 
were seeded in standard culture media at a density of 1x106 per 9 cm dish and allowed 
to attach overnight. The following day, the cells were washed twice in PBS and the 
medium was changed. Each cell line was exposed to three types of media: serum-free 
medium, steroid depleted medium containing 10% charcoal-stripped serum and 
medium containing 10% full foetal calf serum. After 60 hours, which allows for the 
metabolism of intracellular steroid hormones, cell lysates were prepared and western 
blot analysis performed as described above.  
Src inhibitor exposure experiment.  LNCaP and LNCaP-SDM cells were seeded at 
a density of 1x106 per 9 cm Petri dish and cultured using standard culture media until 
80% confluent and then treated overnight with a range of dasatinib concentrations. 
Cell lysates were prepared and western blot analysis performed as described above. 
Dasatinib was provided by Bristol Myers Squibb and made up as 10 mM stock in 
DMSO. 
Immunoprecipitation.  Cell lysates were prepared as described in previous 
sections and samples containing 500 µg of protein in 500 µl incubated with anti-total 
Lyn (1:50 BD Biosciences) or anti-total Src (1:100 Cancer Research UK) at 40C 
overnight. Then, anti-mouse IgG agarose beads (Sigma, UK) were added to the 
samples (20 µl per sample) and further incubated for 1 hour at 40C. Immune 
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complexes were analyzed as per western blot protocol with anti-phospho SrcY419 
antibody (1:10000 Cell Signaling Technologies).  
Cell migration.  To follow random migration, cells were plated at a low density 
(5x104) on glass-bottomed 6-well plates (Iwaki, Japan), allowed to attach overnight 
and then treated with increasing concentrations of dasatinib, diluted in standard 
culture media. Migration was monitored by video time-lapse microscopy for 24 hours 
using a Zeiss Axiovert S100 microscope with x20 objective powered by AQM 
Advance software (Kinetic Imaging, UK).  
Wound healing assay was carried out to investigate the ability of prostate cancer 
cells to migrate into a denuded area in the presence or absence of Dasatinib. LNCaP 
and LNCaP-SDM cells were plated at a density of 1x106 cells per well of a glass-
bottomed six-well plate (Iwaki, Japan). The following day, the wounds through the 
confluent cells monolayer were made using a fine pipette tip, three wound per each 
well. The medium was then replaced with standard for each cell line culture medium 
containing increasing concentrations of dasatinib.  The assay was performed over 24 
hours with images taken from 3 fields per each well every 30 minutes using a Zeiss 
Axiovert S100 microscope at x20 magnification.  Cell migration was measured by 
subtraction of the distance between the edge of the wound at time 0 and 24 hours 
using ImageJ software. 
Cell proliferation.  Proliferation was assessed using the WST-1 assay as per 
manufactures instructions. Cells were seeded in 96 well plates at a density 5x103 cells 
per well in standard culture media, allowed to attach overnight and the following day 
treated with increasing concentrations of dasatinib, DMSO was added to the control 
well. The assay was performed at 48, 72 and 96 hours by adding 10 µL of WST-1 
reagent prior diluted in Electro Coupling Solution (ECS) to each well. The optical 
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absorbance level was measured after 2 hours incubation at 370C using a 96 well 
microplate reader at 450 nm with reference wavelength 600 nm. 
To study the effect of androgens on proliferation in the presence of dasatinib, 
LNCaP and LNCaP-SDM cells were plated in standard culture media for 24 hours 
after which LNCaP cells were placed in the steroid depleted medium containing 10% 
charcoal stripped fetal calf serum and LNCaP-SDM cells in RPMI1640 supplemented 
with 10% full fetal calf serum. WST-1 assay was performed at 48, 72 and 96 hours as 
described above. 
Statistical analysis. 
Statistical analysis was performed using Microsoft Excel and the SPSS statistical 
package (version 9.0). Small changes in protein expression between paired ASPC and 
AIPC tumours could be due to random errors in the assessment of histoscores.  To 
identify individual patients in whom there was strong evidence of a genuine rise or 
fall in protein expression, it was required that the change in expression exceed a 
threshold equal to two standard deviations of the inter-observer difference for that 
protein.  This threshold was chosen because, if there was in reality no difference in 
protein expression between ASPC and AIPC tumours in a given patient, there would 
be only a 5% probability of an apparent difference being observed that exceeded the 
threshold due to random variation.  This assumes that the random variation between 
two different observers assessing the same tumour is of a similar magnitude to the 
random variation that would affect a single observer assessing two different tumours 
with the same level of protein expression. Changes in protein expression in individual 
patients that exceeded this threshold were termed significant. Wilcoxon Signed Rank 
Tests were used to compare expression between ASPC and AIPC tumours. Survival 
analysis including time to relapse, time to death from relapse and overall survival was 
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conducted using the Kaplan-Meier method and curves were compared with the log-
rank test. 
 
Results 
SFK protein expression in ASPC and AIPC.  In order to determine the level of 
Src, Lyn and Fgr expression and activation in the transition from ASPC to AIPC we 
used one hundred paraffin embedded tissue sections taken from fifty patients with 
prostate cancer who underwent hormone-deprivation therapy and subsequently 
developed hormone relapse. Due to tissue heterogeneity, full tissue sections were 
stained using antibodies against total Src, Lyn, Fgr and phospho SrcY419 representing 
an active form of SFKs and phospho SrcY527, a marker suggestive of inactive Src 
(Table 1). The sequences surrounding Src autophosphorylation site tyrosine Y419 are 
highly conserved in the majority of SFK and positive staining using this antibody 
represents autophosphorylation not only of Src but also other Src family members.  In 
our cohort, there was a significant increase in overall pSrcY419 immunostaining in the 
transition from ASPC to AIPC, more intense cytoplasm and membrane staining was 
observed in AIPC samples compared to ASPC (Fig. 1). In addition, although the 
majority of matched specimens on an individual patient basis showed no change in 
expression of pSrcY419 as determined by the weight histoscore in the transition from 
ASPC to AIPC, a subgroup of patients did have tumours that exhibited a rise in 
expression as determined by the weighted histoscore technique in the transition form 
ASPC to AIPC (table 1).  Small changes in protein expression between paired ASPC 
and AIPC tumours could be due to random errors in the assessment of histoscores, 
therefore the mathematic method as described in the methods statistical analysis 
section was employed for selection of patients with genuine rises in expression. 
Changes in protein expression in individual patients that exceeded this threshold were 
 14 
termed an increase in expression.  Using this method 13(26%) and 14(28%) patients 
were noted to have an increase in expression of activated SFKs (pSrcY419) in the 
cytoplasm and membrane respectively (Table 1). In addition, there was an increase in 
overall Lyn membrane immunostaining in the transition from ASPC to AIPC; more 
intense cytoplasm and membrane staining was observed in AIPC samples compared 
to ASPC (although only membrane staining reached significance).  No change in 
expression was observed for Fgr and, interestingly, expression of total and inactive 
forms of Src in the cytoplasm fell significantly after the patients developed hormone 
relapse whereas the membrane staining did not change (Table 1). 
Correlation of SFK expression with clinical parameters. Development of bone 
metastases (as confirmed by bone scans) in patients with advanced prostate cancer is 
the cause for significant morbidity and is considered to be an important negative 
prognostic sign.  In our cohort, following the diagnosis of prostate cancer, the 
majority of the patients (46 or 92%) had bone scans, in 8 patients (16%) it was 
positive, implying the presence of bone metastases, and in 38(76%) it was negative. 
After the development of AIPC, the patients, who had positive bone scans at 
diagnosis and no bone scan after relapse were considered as having bone metastases 
as well as those who had negative bone scans at diagnosis and positive scans at 
relapse (26(52%)).  The membranes in the tumour samples taken from patients with 
AIPC stained more intensely with the phospho-SrcY419 antibody if there was evidence 
of bone metastases (P=0.011)(Fig 2A).  No significant correlation was observed 
between the presence of bone metastases and cytoplasmic staining with antibodies 
against phospho-SrcY419, phospho-SrcY527, total Src, Fgr or Lyn. 
The cohort was then further subdivided into groups according to Gleason grade at 
diagnosis and PSA value at relapse, important prognostic criteria in patients with 
prostate cancer. High or low PSA at relapse were not associated with IHC histoscores 
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and only expression of cytoplasmic Lyn in the hormone refractory tumours was 
associated with Gleason grade (p=0.029)(Fig. 2A). 
Survival analysis.  Use of paired prostate cancer specimens taken from patients 
prior to commencement of hormone manipulation therapy and after androgen escape, 
made it possible to correlate IHC scores of each individual patient with various 
survival parameters including time from diagnosis to biochemical relapse, time from 
relapse to death and overall survival. Statistical analysis revealed that a subset of 
patients, who had an increase in SFK activity (pSrcY419 expression) at the membrane 
in the transition from ASPC to AIPC, had a significantly shorter time to relapse, 
median time from diagnosis to hormone escape in this subgroup of patients was 
1.86(1.36-2.47) years compared to 2.98(1.93-4.63) years for those who had decreased 
membrane signal or no change (P=0.005, Fig. 2B). Furthermore, the time from 
biochemical relapse to death was also reduced: 1.14 (0.58-2.15) years versus 1.87 
(1.1-1.86) years (P=0.011, Fig. 2C).  Therefore the combination of reduced time to 
relapse combined with reduced time to death following relapse resulted in a 
significant reduction in overall survival, median survival for those with an increase in 
membrane pSrcY419 expression was 2.91(Inter Quartile Range 2.42-4.92) years) 
compared to 6.33(IQR 4.15-7.27) years for those patients with tumours that had a 
decrease or no change in pSrcY419 expression (P<0.0001, Fig. 2D).  No association 
with the time to relapse or survival was observed for Fgr, total or inactive forms of 
Src, however an increase in membrane Lyn expression was associated with a shorter 
time to relapse (P=0.022).  Median time from diagnosis to hormone escape in this 
subgroup of patients was 2.29(1.78-2.79) years compared to 3.2(2.45-3.99) years in 
those who had a decreased  membrane signal or no change (P=0.022). This was also 
observed for an increase in cytoplasmic Lyn expression, median time from diagnosis 
to hormone escape in this subgroup of patients was 2.41(2.01-2.73) years compared to 
3.2(1.98-4.45) years in those who had decreased membrane signal or no change 
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(P=0.040). However, no association with time from biochemical relapse to death or 
overall survival were observed. 
SFK activity in prostate cancer cell lines.  Having demonstrated that SFK 
activation may affect survival of patients with AIPC, we examined SFK activity in 
hormone sensitive LNCaP and hormone refractory LNCaP-SDM prostate cancer cell 
lines.  In order to assess the effect of androgen stimulation and withdrawal on Src 
kinase activity, both cell lines were exposed to various culture media including 
serum-free medium, medium containing dextran charcoal-stripped foetal calf serum 
(steroid depleted medium) and full foetal calf serum.  SFK activity in LNCaP cells 
experiencing acute androgen withdrawal in steroid depleted medium was reduced to 
the same degree as in the cells that were serum starved (Fig. 3A).  In LNCaP-SDM 
cells, routinely cultured in charcoal-stripped serum, long-term androgen deprivation 
resulted in higher basal level of SFK activity compared to LNCaP cells in equivalent 
culture conditions. When deprived of growth factors in serum-free medium LNCaP-
SDM cells displayed a further reduction in SFK activity, whereas treatment of these 
cells with full foetal calf serum containing physiological amount of androgens, 
increased SFK activity, although it did not reach the level observed in parental 
LNCaP cells (Fig. 3A).  
Dasatinib inhibits SFK activity in LNCaP and LNCaP-SDM cells.  Dasatinib was 
used to investigate the effects of Src inhibition on LNCaP and LNCaP-SDM cells. 
Treatment of LNCaP and LNCaP-SDM cells with dasatinib resulted in a dose-
dependent reduction of SFK activity using the autophosphorylation of Src at tyrosine 
Y419 as a marker of activation. Complete inhibition of SFK activity in LNCaP cells 
was seen at 50 nM (Fig. 3B). SFK activity was also suppressed in LNCaP-SDM cells 
(Fig. 3C), although complete inhibition was achieved at slightly higher concentrations 
(75 nM). Interestingly, in LNCaP-SDM cells increasing the dose of dasatinib resulted 
in an increase in total Src. FAK phosphorylation on tyrosine Y861 (Src-dependent 
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phosphorylation site) was also inhibited by treatment with dasatinib in both cell lines 
in a dose-dependent manner while the levels of phospho FAKY397 (Src-independent 
autophosphorylation site) and total FAK remained unchanged (Fig. 3B and C). 
Due to cross-reactivity of the phospho-Src Y419 antibody it was necessary to 
immunoprecipitate Src and Lyn to study the effect of dasatinib on individual family 
members.  Dasatinib inhibited Lyn autophosphorylation in both LNCaP and LNCaP-
SDM cells at equivalent concentrations (Fig. 3D).  Higher concentrations were 
necessary to inhibit Src autophoshorylation in the LNCaP-SDM cells (Fig. 3D). 
Dasatinib inhibits prostate cancer cell migration.  Time lapse video microscopy 
was employed to investigate the effect of dasatinib on LNCaP and LNCaP-SDM cell 
migration into a denuded area using a wound healing assay. Both, LNCaP (data not 
shown) and LNCaP-SDM (Fig. 4A and B) cells exhibited a similar dose-dependent 
reduction in migration when treated with increasing concentrations of dasatinib for 48 
hours. LNCaP cells cultured in full medium, containing foetal calf serum were noted 
to have long protrusions, whereas the protrusions, produced by LNCaP-SDM cells 
when kept in androgen depleted medium, rarely exceeded the length of the body of 
the cell. Interestingly, when cultured in the medium containing physiological 
concentrations of androgens (foetal calf serum), the number of LNCaP-SDM cells 
forming long protrusions significantly increased (data not shown).  
We then studied the effect of dasatinib on protrusion dynamics in LNCaP-SDM 
cells. Cells treated with low inhibitor concentrations formed protrusions at 
significantly lower rates than control cells, whereas cells exposed to high 
concentrations of dasatinib failed to produce protrusions. Images of representative 
cells are shown in Fig. 4C and a similar effect was observed in LNCaP cells (data not 
shown). Quantitative analysis revealed that as a result of dasatinib treatment there was 
a dose-dependent reduction in the number of protrusions per cell (Fig. 4D). 
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Effect of dasatinib on prostate cancer cell proliferation.  Growth of hormone 
sensitive LNCaP cells is driven mostly by androgens while hormone refractory 
LNCaP-SDM cells are thought to depend on growth factors transmitting oncogenic 
signals via tyrosine kinases.  Treatment with dasatinib inhibited proliferation of 
hormone-refractory LNCaP-SDM cells in a dose-dependent manner (IC50 500 nM) 
(Fig. 5) at concentrations corresponding to inhibition of SFK activity (Fig. 3C).  
Proliferation of hormone sensitive LNCaP cells was not significantly inhibited by 
dasatinib even at concentrations up to 10 µM (Fig. 5). Interestingly, introduction of 
androgens to the steroid depleted medium, used for routine culture of LNCaP-SDM 
cells, did not rescue proliferation suppressed by dasatinib (data not shown). 
 
Discussion 
Hormone sensitive prostate cancer cells proliferate and migrate as a result of 
androgen stimulation. Androgen deprivation therapy leads to the changes in the way 
prostate cancer cells operate by increasing their sensitivity to the low levels of 
androgens, up regulating various oncogenic molecular pathways where the AR is 
activated by growth factors and antagonists or bypassing AR altogether (2,20). These 
pathways frequently interact or crosstalk, which is why the strategy of inhibiting 
individual proteins or even pathways has not resulted in the development of effective 
therapies. Targeting key tyrosine kinases involved in the interaction between various 
cascades together with individual tumour profiling and combination treatments could 
be used to overcome drug resistance (21).  
Numerous in vitro studies have confirmed the importance of Src in the 
development of prostate cancer and its progression to a hormone independent state 
(19-27). Here, for the first time, we report the association between SFK activity and 
clinical data in prostate cancer patients. Our findings suggest that SFK activity is 
upregulated in a subgroup of patients with AIPC, which ultimately affects their 
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survival. Patients with the increase in SFK activity in the transition from ASPC to 
AIPC live on average a 3.42 years shorter after the diagnosis of prostate cancer is 
made than the patients with the decrease or no change. This difference is dramatic 
given the relatively short overall lifespan of patients with hormone refractory disease. 
Furthermore, an increase in SFK activity in patients with AIPC may result in higher 
likelihood of metastatic disease, which could potentially contribute to the reduction in 
survival. 
It is not entirely clear at the moment which SFK member plays dominant role in 
the transition of prostate cancer to hormone independence. Fgr has previously been 
found amplified in hormone refractory prostate cancer (26), although our data 
suggests that its expression does not seem to change with hormone escape. 
Goldenberg-Furmanov et al. reported that expression of Lyn, another SFK member, 
tends to be higher in poorly differentiated regions of prostatic tumours and Lyn 
deficient mice have underdeveloped prostate gland (28). In this study, we demonstrate 
that expression of Lyn does correlate with Gleason grade and, furthermore, this is a 
feature of hormone refractory prostate cancer. It has been suggested that various SFK 
member may play different role in prostatic oncogenesis (29). Experiments using 
siRNA approach to silence Src or Lyn revealed that although Src knockout had only 
minimal effect on proliferation rate, cell migration was significantly reduced. In 
contrast, silencing Lyn resulted in reduced proliferation, although no migration 
experiment was conducted (28).   
Use of Src kinase inhibitors in prostate cancer cell lines has been the subject of 
several publications. Recchia et al. reported a reduction in PC-3 cells adhesion, 
migration and proliferation when treated with pyrrolopyrimidine class compounds 
(25). Dasatinib (BMS-354825), a selective inhibitor of Src and related kinase Abl, has 
been reported to suppress Src kinase activity at low nanomolar concentrations, reduce 
the phosphorylation of downstream proteins FAK and p130cas and, as a result inhibit 
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DU-145 cell adhesion, migration and invasion (20). In animal models, dasatinib 
treatment was demonstrated to affect primary tumour growth of prostate cancer cells 
implants as well as reduce the rate of lymph node metastases (29). However, the cell 
lines used in these studies do not express AR, which is found in the majority of 
prostate cancer specimens taken from patients with AIPC (30). This is a significant 
drawback given that there is evidence of AR and Src interactions, especially in a low 
androgen environments (31). Park et al. reported the use of a PC-3 cell line 
transfected with functional AR in an animal model, although no in vitro experiment 
was conducted (14). In this study, simulating acute androgen withdrawal by placing 
LNCaP cells in the steroid-depleted medium produced a dramatic reduction in Src 
kinase activity, confirming that Src interaction with AR is important in prostate 
cancer and should not be ignored. LNCaP-SDM cells were developed by gradual 
withdrawal of androgens from the culture medium mimicking hormone deprivation 
therapy; they retain functional AR and, therefore, provide a good model of AIPC.  
Src kinase plays a key role in cell migration by regulating the turnover of focal 
adhesions and adherence junctions. Cell movement is initiated by the focal adhesion 
assembly at the leading edge of the moving cell followed by formation of dynamic 
protrusions allowing the cell to propagate in the direction of movement while cell-cell 
junctions become weaker and focal adhesions at the rear of the moving cell 
disassemble (32). When treated with dasatinib, both hormone sensitive and hormone 
refractory cell lines exhibited reduced migration, which was dose-dependent. The 
cells were not able to produce protrusions or when exposed to lower concentrations of 
dasatinib, produced protrusions at much lower rate than control cells. This finding has 
certain clinical implications: Src inhibitors could be used in both hormone sensitive as 
well as hormone refractory prostate cancer in order to prevent the spread of malignant 
cells and the development of metastatic disease. However, at the moment there are no 
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reliable methods to evaluate this in clinical setting and, therefore, we need to develop 
the necessary tools as a matter of urgency. 
Controversy surrounding the role of Src in cancer cell proliferation is partly due to 
the lack of specificity many small molecule inhibitors often display. Dasatinib, for 
instance, is known to inhibit PDGFRβ, Abl, c-Kit and EphA2 (33-34). Although 
previous studies have shown that Src inhibitors may affect proliferation of prostate 
cancer cells, the concentrations required to elicit this effect considerably exceeded 
those needed to suppress adhesion and migration (34-35). Our experiments showed 
that dasatinib inhibited proliferation of hormone-refractory LNCaP-SDM cells 
whereas proliferation of the hormone sensitive LNCaP cells was not affected.  
However, in a recent publication, it has been demonstrated that dasatinib inhibited 
proliferation of both LNCaP and PC3-MM2GL cell line with dasatinib concentrations 
above 100 nM (30). Thus, proliferation of hormone resistant prostate cancer cells is 
more likely to be affected by SFK inhibitors probably due to their dependence on 
growth factors rather than androgens.  
Although SFK activity could be a contributing factor in the development of 
prostate cancer and its progression to the hormone independent state, only a subgroup 
of patient with AIPC might be suitable for the treatment with Src inhibitors. 
Identifying these patients would provide more targeted approach resulting in the 
treatment being delivered more effectively. Therapeutic strategies employing Src 
inhibitors in combination with conventional anti-androgens, chemotherapy or other 
small molecule inhibitors in patients with prostate cancer should be considered (35). 
As Src inhibitors could potentially be used to prevent the development of metastatic 
disease, methods to assess this in clinical trials are urgently required. 
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Table 1. 
 
Histoscores Number of Patients Antibody 
ASPC AIPC Increase Fall No change 
P value 
pSrcY419       
cytoplasm 45 (18.75-80) 70(40-90) 13(26%) 3(6%) 34(68%) 0.035 
membrane 20(0-60) 50(0-90) 14(28%) 3(6%) 33(66%) 0.017 
pSrcY527       
cytoplasm 80(50-112.5) 50(20-90) 6(12%) 18(36%) 26(52%) 0.002 
membrane 50(20-80) 20(0-70) 13(26%) 21(42%) 16(32%) 0.101 
Total Src       
cytoplasm 130(100-180) 100(80-126.25) 4(8%) 16(32%) 30(60%) 0.009 
membrane 55(20-116.25) 55(30-110) 10(20%) 13(26%) 27(54%) 0.926 
Total Lyn       
cytoplasm 28(5-70) 50(20-80) 17 (34%) 8 (16%) 25 (50%) 0.094 
membrane 38(10-80) 70(35-95) 25 (50%) 6 (12%) 19 (38%) 0.005 
Total FGR       
cytoplasm 65(39-100) 50(30-78) 8 (16%) 15 (30%) 27 (54%) 0.104 
membrane 95(69-112) 90(63-108) 8 (16%) 14 (28%) 28 (56%) 0.567 
 
Protein expression for each antibody including median histoscores and inter-quartile 
ranges. Membrane and cytoplasm staining was scored separately and the patients were 
subdivided into those who had an increase in expression from ASPC to AIPC, 
decrease and no change. The difference in staining between ASPC and AIPC samples 
was assessed by Wilcoxon signed rank test. 
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Fig. 1. Immunohistochemistry analysis of pared prostate cancer samples taken prior to 
the initiation of hormone deprivation therapy and following hormone relapse. 
Expression of (A) pSrcY419, (B) pSrcY527 (C) total Src and (D) Lyn (E) Fgr.  
Magnification x40. 
 
Fig. 2.  
(A)Relationship between membrane pSrcY419 and presence of bone metastasis at 
relapse and cytoplasmic Lyn expression in hormone refractory tumours and Gleason 
grade.  
Survival analysis of membrane immunostaining with anti-phospho-SrcY419 antibody 
in transition from ASPC to AIPC. Kaplan-Meier survival curves plotting time (B) 
from prostate cancer from diagnosis to hormone relapse, (C) from hormone relapse to 
death and (D) from prostate cancer diagnosis to death. Dashed lines represent patients 
who had an increase in immunohistoscores in the transition from hormone sensitive to 
hormone resistant prostate cancer whereas solid lines reflect the patients who had 
decrease or no change.  
 
Fig. 3. Dasatinib inhibits phosphorylation SFKs and downsteam marker FAK. (A) 
LNCaP and LNCaP-SDM cells where cultured in media containing no serum (serum-
starved, SS), dextran-charcoal stripped fetal calf serum (steroid depleted medium, 
SDM) and fetal calf serum (full medium, FM). Cell lysates were immunoblotted with 
anti-phospho-SrcY419, anti-Src and anti-tubulin antibodies.  (B) LNCaP cells and (C) 
LNCaP-SDM cells were exposed to increasing concentrations of dasatinib in standard 
corresponding culture media for 16 hours.  Cell lysates were immunoblotted with 
anti-phospho-SrcY419, anti-phospho-FAK, anti-FAK, anti-Src and anti-tubulin 
antibodies.  (D) LNCaP and LNCaP-SDM cells were exposed to increasing 
concentrations of dasatinib in standard corresponding culture media for 16 hours.  
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Cell lysates were then immunopreciptated with either Src or Lyn specific antibodies 
and probed with anti-phospho-SrcY419 antibody. 
 
Fig. 4. Dasatinib inhibits motility of LNCaP-SDM cells. (A) A wound healing assay 
performed using LNCaP-SDM cells exposed to a range of dasatinib concentrations.  
Images were taken after 48 hours and show the relative closure of the wound.  (B) 
The difference in distance (expressed in nm) between the edge of wounds at the 
beginning of the experiment and after 48 hours observed by time lapse microscopy 
were plotted against inhibitor concentration.  Each value represents the mean + S.D. 
of three separate measurements (three wounds per well). (C)  LNCaP-SDM cells were 
plated at low density and exposed to increasing concentrations of dasatinib for 24 
hours. Motility was observed by time lapse microscopy and separate pictures were 
taken from the stacks at 4 hourly intervals.  (D) The number of protrusions produced 
by the cells over 24 hours in each concentration of inhibitor was calculated. Values 
are expressed as the mean + S.D. of three individual fields, each field containing 
around 60 cells.  Experiments were repeated three times. 
 
Fig. 5. Dasatinib inhibits proliferation of LNCaP-SDM cells.  Cells were plated on 96 
well plates and after 24 hours were treated with a range of dasatinib concentrations. 
After 96 hours a WST-1 assay was performed.  The values reflect the mean + S.D. of 
6 wells, presented as percentages of the untreated control.  Experiments were repeated 
three times. 
 
